1	Performance of At-Home Self-Collected Saliva and Nasal-Oropharyngeal Swabs in the						
2	Surveillance of COVID-19						
3 4 5	Running Title: At-Home Self-Collected Samples in COVID-19 Diagnosis						
6	Paulo H. Braz-Silva, <sup>a,b*</sup> Ana C. Mamana, <sup>a</sup> Camila M. Romano, <sup>a</sup> Alvina C. Felix, <sup>a</sup>						
7	Anderson V. de Paula, <sup>a</sup> Noeli E. Fereira, <sup>a</sup> Lewis F. Buss, <sup>a</sup> Tania R. Tozetto-Mendoza, <sup>a</sup>						
8	Rafael A. V. Caixeta, <sup>b</sup> Fabio E. Leal, <sup>c</sup> Regina M. Z. Grespan, <sup>c</sup> João C. S. Bizário, <sup>c</sup> Andrea						
9	B. C. Ferraz, <sup>c</sup> Dipak Sapkota, <sup>d</sup> Simone Giannecchini, <sup>e</sup> Kelvin K. To, <sup>f,g,h</sup> Alain Doglio, <sup>i</sup>						
10	Maria C. Mendes-Correa <sup>a</sup>						
11	a. Laboratory of Virology (LIM-52), Institute of Tropical Medicine of São Paulo, School of Medicine,						
12	University of São Paulo, São Paulo, Brazil						
13	b. Department of Stomatology, School of Dentistry, University of Sao Paulo, Sao Paulo, Brazil						
14	c. Municipal University of São Caetano do Sul, São Caetano do Sul, Brazil						
15	d. Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway						
16	e. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy						
17	f. State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology, Carol Yu						
18	Centre for Infection, Li KaShing Faculty of Medicine of the University of Hong Kong, Special						
19	Administrative Region, China						
20	g. Department of Microbiology, Queen Mary Hospital, Hong Kong Special Administrative Region,						
21	China						
22	h. Department of Clinical Microbiology and Infection Control, The University of Hong Kong –						
23	Shenzhen Hospital, Shenzhen, China						
24	i. Laboratory MICORALIS (Microbiologie Orale, Immunité et Santé) School of Dentistry,						
25	University of Côte d'Azur, Nice, France						
26	* Corresponding author:						
27	Paulo H. Braz-Silva, DDS, PHD						
28	Laboratório de Virologia - Instituto de Medicina Tropical de São Paulo – FMUSP						
29	Av. Dr. Enéas Carvalho de Aguiar, 470 - Jardim America, São Paulo – Brazil - 05403-000						

30 NOFE http://www.esearch.that has not been certified by peer review and should not be used to guide clinical practice.

#### 31 ABSTRACT

32 SARS-CoV-2 quickly spread in the worldwide population by contact with oral and respiratory secretions of infected individuals, imposing social restrictions to control the 33 34 infection. Massive testing is essential to breaking the chain of COVID-19 transmission. 35 The aim of this study was to compare the performance of at-home self-collected samples 36 - saliva and combined nasal-oropharyngeal swabs (NOP) - for SARS-CoV-2 detection in 37 a telemedicine platform for COVID-19 surveillance. We analyzed 201 patients who met the criteria of suspected COVID-19. NOP sampling were combined (nostrils and 38 39 oropharynx) and saliva collected using a cotton pad device. Detection of SARS-COV-2 40 was performed by using the Altona RealStar® SARS-CoV-2 RT-PCR Kit 1.0. According 41 to our data, there was an overall significant agreement ( $\kappa$  coefficient value of 0.58) between the performances of saliva and NOP. Assuming that positive results in either 42 43 sample represent true infections, 70 patients positive for SARS-CoV-2 were identified, 44 with 52/70 being positive in NOP and 55/70 in saliva. This corresponds to sensitivities of 45 74.2% (95% CI; 63.7% to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for 46 saliva. We also found a strong correlation ( $\beta$ -coefficients < 1) between the cycle threshold 47 values in saliva and NOP. Ageusia was the only symptom associated with patients SARS-48 CoV-2 positive only in NOP (p=0.028). In conclusion, our data show the feasibility of using at-home self-collected samples (especially saliva), as an adequate alternative for 49 50 SARS-CoV-2 detection. This new approach of testing can be useful to develop strategies 51 for COVID-19 surveillance and for guiding public health decisions.

52

53 Keywords: Saliva; Coronavirus; PCR; Primary Health Care; Infection Control;
54 Telemedicine

55

### 56 INTRODUCTION

57 Rapid and accurate diagnostic tests are essential for controlling the SARS-CoV-2 58 pandemic. Nevertheless, biological specimen collection is an important logistic challenge 59 to provide massive testing (1-3). The possibility to use self-collected samples for COVID-60 19 testing offers several advantages, especially to minimize the risk of exposing 61 healthcare workers to the virus, since self-collection does not require direct involvement 62 of trained personnel in the sample collection(4, 5). Recently publications have been 63 showed a similar sensitivity between saliva samples and nasal swabs collected by health-64 workers and those collected by a patient for COVID-19 molecular diagnosis, thus providing an important background for the choice of this strategy for surveillance of 65 66 COVID-19(6-8).

Saliva has been described as a good alternative for SARS-CoV-2 detection, showing additional advantages compared to swab collection(9-12). Saliva collection does not cause discomfort or nasal bleeding to patients, does not require swab collectors or personal protective equipment, which are currently in short-supply in the market(3). In addition, saliva allows examination of several biomarkers, which could be useful as molecular signatures for patient stratification regarding infection severity(10, 13, 14).

In a pandemic scenario, at-home self-collection of samples plays a key role in the surveillance and control of the infection by allowing the patient with clinical suspicion of COVID19 to have access to proper healthcare and quick isolation of the confirmed cases(4, 5). Recently published studies show that 80-85% of individuals infected with SARS-CoV-2 have few or no symptoms, while 15-20% develop more severe disease, often associated with advanced age or other co-morbidities(15).

79 The Corona São Caetano program is a primary care initiative providing specific
80 home care to all residents of São Caetano do Sul, state of São Paulo, Brazil. This program

started in April 2020 due to the increasing number of COVID-19 cases in the country.
Self-collection of nasal-oropharyngeal swabs has been used to obtain samples for
diagnosis since the beginning of the epidemics, with excellent results, as hospitalization
rate was less than 3% among the patients enrolled in the program(16).

The aim of this study was to compare the performance of two different at-home self-collected samples - saliva and combined nasal-oropharyngeal swabs (NOP) - for COVID-19 molecular diagnosis in the community patients outside the healthcare facilities.

89

#### 90 PATIENTS AND METHODS

91 The present study was developed in a telemedicine platform for COVID-19
92 surveillance called "Corona São Caetano". Residents of the municipality aged 12 years
93 or older who had suspected symptoms were encouraged to contact the program via
94 website or by phone. They were invited to complete a screening questionnaire including
95 socio-demographic data, information on type, onset and duration of the symptoms.

96 In the last two weeks of May 2020, a serie of 201 consecutive patients 97 participating to the program were included in the present study. The patients met the defined criteria of suspected COVID-19 (i.e., having at least two of the following 98 99 symptoms: fever, cough, sore throat, coryza or change in/loss of smell [anosmia]; or one 100 of these symptoms plus at least two other symptoms consistent with COVID-19) were 101 further evaluated. These patients were then called by a healthcare professional in order to 102 complete a risk assessment. All pregnant women and patients meeting pre-defined 103 screening criteria for severe disease were advised to attend a hospital service. All the 104 other patients were offered a home visit for self-collection of saliva and NOP samples.

Patients testing RT-PCR positive for SARS-CoV-2 were followed up for 14 days
(a maximum of 7 phone calls) after completion of their initial questionnaire, whereas

those testing negative were followed up in the primary healthcare program. The patients
were asked to contact the platform for a new consultation if they developed new
symptoms.

This study was conducted according to ethical standards defined by institutional and national research ethics committees and the Helsinki Declaration of 1964, including subsequent amendments or comparable ethical standards, and approved by the Clinics Hospital Research Ethics Committee of the University of São Paulo School of Medicine under protocol number 3.979.632. Informed consent was obtained from all the individuals enrolled in this study. This study was designed conform to STROBE Guidelines.

116

#### **117 Sample Collection**

118 NOP sampling were combined (both nostrils and oropharynx) using commercial 119 flocked swabs with plastic applicators (Goodwood medical care Ltd., Jinzhou, China). Saliva samples were collected using a cotton pad device - Salivette™ (SARSTEDT AG 120 121 & CO. KG, Nümbrecht, Germany). In order to provide guidance on self-collection 122 procedures, a link to an instructional video was sent to each participant before the home 123 visit. Briefly, patients were instructed to use the swabs in both nostrils and posterior 124 region of the mouth and put both swabs into a tube containing saline solution. For saliva 125 collection, they were instructed to chew carefully a cotton pad for one minute and put it 126 into a specific tube. The samples were collected during the morning hours and the 127 participants were instructed to avoid eating, drinking or toothbrushing at least one hour 128 before the saliva collection. In accordance with the Corona São Caetano Program 129 procedures, samples were immediately put in a cool box (2-8°C) and stored at 4°C in a 130 fridge until shipment to the lab by a specialized carrier in the afternoon the same day.

#### 132 RNA Extraction and Real Time PCR

- To recover the saliva from the devices, the tubes were centrifuged at 5,000g for 5
  minutes. Total nucleic acid was extracted from 200 µl of the saline solution containing
  NOP and recovered saliva by using the NucliSENS EasyMag (BioMérieux, Durham,
  North Carolina, USA) automated DNA/RNA extraction platform.
- Detection of SARS-COV-2 RNA was performed by using the Altona RealStar®
  SARS-CoV-2 RT-PCR Kit 1.0 (altona Diagnostics GmbH, Hamburg, Germany) which
  employs a B-COV specific probe directed to gene E and a SARS-COV-2-specific probe
  directed to gene S. Results were considered positive when one or both genes were
  amplified with a cycle threshold (Ct) < 40.</li>
- 142

## 143 Statistical Analysis

Cohen's kappa coefficient (κ) was used to measure agreement between RT-PCRbased detection of SARS-COV-2 in saliva and NOP swabs. The sensitivity of each
method was calculated assuming that positive cases in either sample type represented true
positives, with 95% confidence intervals being calculated by using the exact method.

Next, we defined four analytic groups as follows: NOP-/saliva- (G1); NOP/saliva+ (G2); NOP+/saliva- (G3); NOP+/saliva+ (G4). In order to identify clinical
features associated with positivity in NOP and saliva, we specifically compared groups
G2 to G4, G3 to G4, and G2 to G3. We used chi-squared test and Wilcoxon's rank-sum
test to compare clinical features (i.e. age, gender, symptoms and onset of illness) between
the patients in these groups.

We then explored the relationship between RT-PCR cycle threshold (Ct) and sample type. We first analyzed group G4 (NOP+/saliva+) and assessed the association between Ct values by using the simple linear regression. Differences in the distribution

of Ct values using NOP and saliva were assessed with paired Wilcoxon's rank-sum test.
We also assessed the association between time from symptom onset and collection of
saliva and NOP by using the simple linear regression. Statistical significance was set at
0.05. All analyses were performed by using the R Statistical Software, version 3.6.3.

161

#### 162 **RESULTS**

For the current study, 201 consecutive patients participating to the Corona São
Caetano program and who met the suspected COVID-19 case definition were included.
RT-PCR- based COVID-19 testing was performed in samples from NOP and saliva and
results are shown in Table 1.

167 Overall, 16,4 % (33/201) of the results were discordant giving a moderate 168 agreement between the both sampling methods with a Cohen's kappa coefficient of 0.58. 169 Overall, assuming that positive test results in either sample type represent true infections 170 around 35% of patients (n = 70) were identified to be positive with COVID-19, while 26 171 % (n = 52) and 27 % (n = 55) were positive based on NOP or saliva detection, 172 respectively. This corresponds to sensitivities of 74.2% (95% CI; 63.7% to 83.1%) for 173 NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva samples. Of note, 9% (n=18) and 174 7% (n=15) resulted saliva or NOP single positive, respectively.

175

# Associations between Clinical Features and SARS-CoV-2 Positivity in Saliva and NOP samples using RNA RT-PCR

# To investigate relationship between SARS-CoV-2 status in NOP and saliva and demographic and clinical features, patients were categorized in 4 groups (G1 to G4) (Table 2); NOP and saliva SARS-CoV-2 negative patients were grouped in G1 (NOPls1 /saliva-, n = 131); NOP-/saliva+ patients in G2 (n = 18); NOP+/saliva- in G3 (n = 15) and NOP+/saliva+ in G4 (n = 37). We didn't found any significant relationship regarding the

183 demographic data of patients in the different groups, although the sex ratio may be 184 different in G2 as compared to G4. Also, no significant correlation was found regarding 185 clinical symptoms, only ageusia appears to be more prevalent in patients with positivity 186 of SARS-CoV-2 in NOP (p = 0.028). Interestingly, the delay between clinical symptoms 187 onset and time of sample collection was significantly shorter (p < 0.05) in G2 as compared 188 to G3 and G4, suggesting that patients with simultaneous SARS-CoV-2 positivity in NOP 189 and saliva (G4-patients) were more prompt to quickly display clinical symptoms (Table 190 2).

191

#### **192 RT-PCR Cycle Thresholds in Saliva and NOP Samples**

193 In order to investigate the relationship between RT-PCR cycle threshold (Ct) and 194 sample type (saliva or NOP), we first compared the Ct values from G4 (NOP+/saliva+, n 195 =37) and assessed the association between Cts using simple linear regression. We found 196 a strong correlation between the Ct values in saliva and naso/oropharyngeal samples (Figure 1). The coefficients of the regression lines ( $\beta$ ) were 0.79 (p < 0.001) and 0.74 (p 197 198 = 0.002) for E and S genes, respectively. A  $\beta$ -coefficient < 1 indicated that, in patients 199 with SARS-CoV-2 positivity in NOP and saliva (G4), Cts tended to be higher in saliva 200 then in NOP (also see Figure 2A).

Next, we compared the Ct values between the groups G3 (NOP+/saliva-) and G4 (NOP+/saliva+). It was observed that the cycle threshold values were lower in patients positive in both NOP and saliva samples (median [IQR], 21.5 [19 - 27]) compared to those positive only in NOP samples (29 [25 - 33], P = 0.01, Wilcoxon's rank-sum test) for gene E. Moreover, these results were for gene S (Figure 2B).

- 206
- 207
- 208

#### 209 Relationship between timing of sample collection and SARS-CoV-2 detection

Because timing of sample collection is a critical parameter of SARS-CoV-2
diagnosis, we further investigate the possible relationship between NOP and saliva
SARS-CoV-2 detection and the delay between clinical symptom onset and timing of
sample collection. Although Ct values tended to be higher at later periods from the onset
of symptoms, this did not reach statistical significance (Figure 3).

215

#### 216 **DISCUSSION**

217

We prospectively analyzed a cohort of patients with mild symptoms of COVID-19 to assess the diagnostic performance of at-home self-collection of combined nasooropharyngeal swabs (NOP) and saliva samples.

221 According to our data, there was an overall significant agreement ( $\kappa$  coefficient 222 value of 0.58) between the performances of saliva and NOP samples in the diagnosis of 223 COVID-19. Assuming that positive results in either sample type represent true infections, 224 a total of 70 patients positive for SARS-CoV-2 were identified, with 52/70 being positive 225 in NOP and 55/70 in saliva. This corresponds to sensitivities of 74.2% (95% CI; 63.7% 226 to 83.1%) for NOP and 78.6% (95% CI; 67.6% to 86.6%) for saliva samples. We also 227 found a strong correlation ( $\beta$ -coefficients < 1) between the cycle threshold (Ct) values in 228 saliva and NOP samples. However, the Ct values for the studied genes tended to be higher 229 in saliva than in NOP samples.

The use of saliva to detect SARS-CoV-2 has been extensively analyzed by different authors, showing that saliva can be used as an alternative sample to nasopharyngeal swabs for COVID-19 molecular diagnosis(9, 10). The sensitivity found in their studies varied from 81% to 100%(11, 12, 17-21). The majority of the studies were conducted with hospitalized patients presenting more severe clinical forms of the disease,

or patients attending a health care unit. It is important to highlight that even with a
different population and different saliva collection (i.e. cotton pad device), we found
similar sensitivity values.

To the best of our knowledge, the present study is the first one in the literature to prospectively examine the performance of at-home self-collected saliva and NOP, in a telemedicine based platform for COVID-19 surveillance. This is highly desirable in a pandemic scenario as it contributes to minimizing the risk of infection transmission in these settings. Additionally, it significantly reduces the workload burden of the healthcare units.

244 According to our results there was a moderate, but very significant, agreement ( $\kappa$ 245 coefficient value of (0.58) between the performances of both sampling methods (NOP and 246 saliva) in the diagnosis of COVID-19. This good overlap between both specimen types 247 was in line with others studies where in general the agreement rate observed varied from 248 0.45 to 1(11, 22). In our study for around 16% of patients, RT-PCR results gave 249 discordant results between both sampling methods. This variation in agreement may be 250 associated with different factors, such as clinical characteristics of the population, 251 diagnostic kits, saliva collection methods, among others. However, these inconsistent 252 results are likely to be related to the fact the virus can reach oral and nasopharyngeal area 253 with different kinetics being not always present at the same time in both sites as 254 previously reported(23).

It has been postulated that there is a minimum of three different pathways for SARS-CoV-2 to reach the saliva: firstly, from the lower and upper respiratory tract; secondly, presence in the blood and gingival crevicular fluid; and thirdly, through salivary gland infection, with subsequent release of viral particles into the saliva via salivary ducts(10, 24, 25). It is believed that the highest viral concentration observed in saliva is

derived from the respiratory tract(12). Therefore, the finding of viruses in saliva would
be expected only in cases with a higher viral load, since the viral particles observed in the
saliva also depends on the amount of viruses coming from the respiratory tract. However,
the fact that in our study 9% of the samples were positive in saliva in absence of NOP
positivity could be indicative that at least in a minimal part the virus comes from salivary
origin.

266 In addition, based on the 37 patients positive in both saliva and NOP samples, 267 we found a strong correlation between cycle threshold (Ct) values in saliva and those in 268 NOP samples, indicating that Ct values tended to be higher in saliva than in NOP samples 269 ( $\beta$ -coefficients < 1). When we compared the cases positive in both methods to those 270 positive in NOP only, it was found that Ct values were lower in the first group. This 271 finding reinforces the idea that the viral load has to be higher (lower Ct) in order to be 272 positive in the saliva. Clearly, according to our results, the viral load influenced the 273 results. Only cases with a higher viral load (lower Ct) were positive in both methods, 274 whereas cases with higher Ct values were positive in NOP samples only.

Some studies have compared the viral load between nasopharyngeal swab and saliva samples, showing a tendency for a higher viral load (or lower Cts) in nasopharyngeal swabs(10, 19). The severity of the cases included and the time elapsed between collection of material and onset of symptoms are essential information to interpret correctly these results, since the sensitivity of the diagnostic methods varies according to these variables.

When we compared the chance of identifying the virus in saliva and NOP samples in relation to the time interval between onset of symptoms and sample collection time, it was observed that the identification of the virus in both samples were associated with a shorter interval of time. These results stress the importance of early diagnosis of COVID-

285 19, in which sample should be collected within the first days of symptoms, thus 286 minimizing the loss of sensitivity of the molecular diagnosis(26). Different studies have 287 analyzed the SARS-CoV-2 shedding in different biologic specimens, reporting that viral 288 loads from upper respiratory tract samples peak within a week of symptom onset and 289 follow a relatively consistent downward trajectory(27). Viral load in other biologic 290 specimens, including saliva, follows the same trajectory(28). However, according to these 291 studies, viral load does not seem to be as high as that observed in respiratory tract samples. 292 Therefore, our findings are in line with these observations.

293 Chemosensory deficits associated with SARS-CoV-2 infection are quite frequent 294 among patients with mild or moderate disease, considered a very early symptom. 295 Interestingly, in our study ageusia was the only symptom statistically associated with 296 patients SARS-CoV-2 positive only in NOP samples (G3; p=0.028). This results 297 corroborate with the role of the neurotropic and neuro-invasive characteristics of 298 coronaviruses in the pathogenesis of ageusia, more than a local infection of the gustatory 299 buds(29).

Recent studies comparing samples collected by a specialized health-workers and self-collected by the patients for COVID-19 molecular diagnosis showed that both methods had similar sensitivity, which highlights the reliability of self-collection as a public health strategy for COVID-19 surveillance(6-8). Our results corroborate these findings as they showed that both self-collected samples had good sensitivity, especially the saliva, with 78.6% (95% CI; 67.6% to 86.6%).

The present study showed that self-collection of saliva and NOP for diagnosis of COVID-19 is feasible in the studied population. Given the similar sensitivities of saliva and NOP samples for detection of SARS-CoV-2 in patients with mild symptoms, it is expected that self-collection of either sample can be valuable in the surveillance of

COVID-19 at a population level(30). Moreover by simplifying the procedure and, above all, avoiding the need for the patient to go to a specialized laboratory, this innovative approach can improve COVID-19 diagnosis, notably allowing the sample to be collected as soon as possible after appearance of the first symptoms. However, in this sense, the ease of collection and feasibility for examination of molecular biomarkers for disease stratification and prognosis justify the use of self-collected saliva as a preferred biological sample(2, 26).

317 As the main limitation of this study, we can cite the non-inclusion of318 asymptomatic individuals in the platform of COVID-19 surveillance.

In conclusion, our data show the possibility of using at-home self-collected samples (especially saliva), as an adequate alternative for SARS-CoV-2 detection. This new approach of testing can be useful to develop strategies for COVID-19 surveillance and for guiding public health decisions.

323

#### 324 Author Contributions

325 P.H. Braz-Silva, M. C. Mendes-Correa contributed to conception and study design, 326 analysis and interpretation of data, drafted and critically revised the manuscript; A.C. 327 Mamana, C. M. Romano, L. F. Buss contributed to study design, acquisition, analysis, 328 and interpretation of data, drafted the manuscript; A. C. Felix, A. V. de Paula, N. E. 329 Ferreira contributed to acquisition, analysis, and interpretation of data, critically revised 330 the manuscript; T. R. Tozetto-Mendoza contributed to conception of the study, 331 interpretation of data, critically revised the manuscript; R. A. V. Caixeta contributed to 332 analysis and interpretation of data, drafted the manuscript; F. E. Leal, R. M. Z. Grespan, 333 J. C. S. Bizário, A. B. C. Ferraz contributed to conception and study design, acquisition 334 of data, critically revised the manuscript; D. Sapkota, S. Giannecchini, K. K. To, A.

335 Doglio contributed to analysis and interpretation of data, drafted and critically revised the
336 manuscript. All authors gave their final approval and agree to be accountable for all
337 aspects of the work.

## 339 Acknowledgements

This study was supported by the Internal funding from the Hospital das Clínicas of the
University of São Paulo School of Medicine, São Paulo, Brazil. We would like to thank
José Tadeu Sales for the language correction of the manuscript. The authors declare no
potential conflict of interest with respect to the authorship and/or publication of this
article.

## 360 **References**

- Landry ML, Criscuolo J, Peaper DR. 2020. Challenges in use of saliva for detection
   of SARS CoV-2 RNA in symptomatic outpatients. J Clin Virol 130:104567.
- Yokota I, Shane PY, Okada K, Unoki Y, Yang Y, Inao T, Sakamaki K, Iwasaki S,
   Hayasaka K, Sugita J, Nishida M, Fujisawa S, Teshima T. 2020. Mass screening of
   asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis
   doi:10.1093/cid/ciaa1388.
- Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF,
   Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M,
   Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Dela Cruz CS, Farhadian
   SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL. 2020. Simply saliva:
   stability of SARS-CoV-2 detection negates the need for expensive collection
   devices. medRxiv doi:10.1101/2020.08.03.20165233.
- Hall EW, Luisi N, Zlotorzynska M, Wilde G, Sullivan P, Sanchez T, Bradley H, Siegler
   AJ. 2020. Willingness to Use Home Collection Methods to Provide Specimens for
- 375 SARS-CoV-2/COVID-19 Research: Survey Study. J Med Internet Res 22:e19471.
- Valentine-Graves M, Hall E, Guest JL, Adam E, Valencia R, Shinn K, Hardee I,
   Sanchez T, Siegler AJ, Sullivan PS. 2020. At-home self-collection of saliva,
   oropharyngeal swabs and dried blood spots for SARS-CoV-2 diagnosis and
   serology: Post-collection acceptability of specimen collection process and
   patient confidence in specimens. PLoS One 15:e0236775.
- Therchilsen JH, von Buchwald C, Koch A, Dam Nielsen S, Rasmussen DB, Thudium
   RF, Kirkby NS, Raaschou-Pedersen DET, Bundgaard JS, Iversen K, Bundgaard H,
   Todsen T. 2020. Self-Collected versus Healthcare Worker-Collected Swabs in the

- 384 Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2. Diagnostics385 (Basel) 10.
- 386 7. Tu YP, Jennings R, Hart B, Cangelosi GA, Wood RC, Wehber K, Verma P, Vojta D,
- 387 Berke EM. 2020. Swabs Collected by Patients or Health Care Workers for SARS-
- 388 CoV-2 Testing. N Engl J Med 383:494-496.
- 389 8. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir SM.
- 3902020. Self-Collected Anterior Nasal and Saliva Specimens versus Healthcare391Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-
- 392 CoV-2. J Clin Microbiol doi:10.1128/JCM.01824-20.
- 393 9. Fernandes LL, Pacheco VB, Borges L, Athwal HK, de Paula Eduardo F, Bezinelli L,
- Correa L, Jimenez M, Dame-Teixeira N, Lombaert IMA, Heller D. 2020. Saliva in
  the Diagnosis of COVID-19: A Review and New Research Directions. J Dent Res
  doi:10.1177/0022034520960070:22034520960070.
- Sapkota D, Soland TM, Galtung HK, Sand LP, Giannecchini S, To KKW, Mendes Correa MC, Giglio D, Hasseus B, Braz-Silva PH. 2020. COVID-19 salivary signature:
   diagnostic and research opportunities. J Clin Pathol doi:10.1136/jclinpath-2020 206834.
- Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M,
  Vijayakumar P, Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone
  ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M,
  Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S,
  Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE, Park
  A, Silva J, Song E, Takahashi T, Taura M, Weizman OE, Wong P, Yang Y, Bermejo
  S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki A,

- 408 Grubaugh ND, et al. 2020. Saliva or Nasopharyngeal Swab Specimens for 409 Detection of SARS-CoV-2. N Engl J Med 383:1283-1286.
- 410 12. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM,
- 411 Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW,
- 412 Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. 2020. Temporal
- 413 profiles of viral load in posterior oropharyngeal saliva samples and serum
- 414 antibody responses during infection by SARS-CoV-2: an observational cohort
- 415 study. Lancet Infect Dis 20:565-574.
- 416 13. Henrique Braz-Silva P, Pallos D, Giannecchini S, To KK. 2020. SARS-CoV-2: What
- 417 can saliva tell us? Oral Dis doi:10.1111/odi.13365.
- 418 14. Adeoye J, Thomson P. 2020. 'The Double-Edged Sword' An hypothesis for Covid419 19-induced salivary biomarkers. Med Hypotheses 143:110124.
- Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020. Substantial
  undocumented infection facilitates the rapid dissemination of novel coronavirus
  (SARS-CoV-2). Science 368:489-493.
- 422 (SARS-COV-2). Science 368:489-493.
- 423 16. Leal FE M-CM, Buss LF, et al. 2020. A primary care approach to the COVID-19
- 424 pandemic: clinical features and natural history of 2,073 suspected cases in the
- 425 Corona Sao Caetano programme, Sao Paulo, Brazil. medRxiv
  426 doi:10.1101/2020.06.23.20138081
- Pasomsub E, Watcharananan SP, Boonyawat K, Janchompoo P, Wongtabtim G,
  Suksuwan W, Sungkanuparph S, Phuphuakrat A. 2020. Saliva sample as a noninvasive specimen for the diagnosis of coronavirus disease 2019: a crosssectional study. Clin Microbiol Infect doi:10.1016/j.cmi.2020.05.001.

431 18. To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, Leung WS, Chik TS, Choi CY,

- 432 Kandamby DH, Lung DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF,
- 433 Yuen KY. 2020. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin
  434 Infect Dis 71:841-843.
- 435 19. Williams E, Bond K, Zhang B, Putland M, Williamson DA. 2020. Saliva as a
  436 Noninvasive Specimen for Detection of SARS-CoV-2. J Clin Microbiol 58.
- 437 20. Azzi L, Carcano G, Gianfagna F, Grossi P, Gasperina DD, Genoni A, Fasano M,
  438 Sessa F, Tettamanti L, Carinci F, Maurino V, Rossi A, Tagliabue A, Baj A. 2020.

439 Saliva is a reliable tool to detect SARS-CoV-2. J Infect 81:e45-e50.

- 440 21. Cheuk S, Wong Y, Tse H, Siu HK, Kwong TS, Chu MY, Yau FYS, Cheung IYY, Tse
- 441 CWS, Poon KC, Cheung KC, Wu TC, Chan JWM, Cheuk W, Lung DC. 2020. Posterior
  442 oropharyngeal saliva for the detection of SARS-CoV-2. Clin Infect Dis
  443 doi:10.1093/cid/ciaa797.
- Jamal AJ, Mozafarihashjin M, Coomes E, Powis J, Li AX, Paterson A, Anceva-Sami
  S, Barati S, Crowl G, Faheem A, Faroogi L, Khan S, Prost K, Poutanen S, Taylor M,
- 446 Yip L, Zhong XZ, McGeer AJ, Mubareka S, Toronto Invasive Bacterial Diseases 447 Network C-I. 2020. Sensitivity of nasopharyngeal swabs and saliva for the 448 detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin 449 Infect Dis doi:10.1093/cid/ciaa848.
- Rao M, Rashid FA, Sabri F, Jamil NN, Zain R, Hashim R, Amran F, Kok HT, Samad
  MAA, Ahmad N. 2020. Comparing nasopharyngeal swab and early morning saliva
  for the identification of SARS-CoV-2. Clin Infect Dis doi:10.1093/cid/ciaa1156.
- 453 24. Xu J, Li Y, Gan F, Du Y, Yao Y. 2020. Salivary Glands: Potential Reservoirs for
  454 COVID-19 Asymptomatic Infection. J Dent Res 99:989.

- 455 25. Kheur S, Kheur M, Gupta AA, Raj AT. 2020. Is the gingival sulcus a potential niche
  456 for SARS-Corona virus-2? Med Hypotheses 143:109892.
- 457 26. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T, Horiuchi M,
  458 Kato K, Imoto Y, Iwata M, Mimura S, Ito T, Tamura K, Kato Y. 2020. Clinical
  459 Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR
  460 (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal
  461 Amplification, and a Rapid Antigen Test To Diagnose COVID-19. J Clin Microbiol
  462 58.
- 463 27. Weiss A, Jellingso M, Sommer MOA. 2020. Spatial and temporal dynamics of
  464 SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis.
  465 EBioMedicine 58:102916.
- 466 28. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, Xie G, Lin S, Wang R, Yang X, Chen W,

Wang Q, Zhang D, Liu Y, Gong R, Ma Z, Lu S, Xiao Y, Gu Y, Zhang J, Yao H, Xu K, Lu
X, Wei G, Zhou J, Fang Q, Cai H, Qiu Y, Sheng J, Chen Y, Liang T. 2020. Viral load
dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang
province, China, January-March 2020: retrospective cohort study. BMJ
369:m1443.

- 472 29. Samaranayake LP, Fakhruddin KS, Panduwawala C. 2020. Sudden onset, acute
  473 loss of taste and smell in coronavirus disease 2019 (COVID-19): a systematic
  474 review. Acta Odontol Scand 78:467-473.
- Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, Chong S, Newcombe
  JP, Siversten T, Hadlow N. 2020. Self-collection: An appropriate alternative
  during the SARS-CoV-2 pandemic. J Clin Virol 128:104417.

478

# 479 Table 1 - Comparison of SARS-CoV-2 RNA status in saliva and NOP samples in 201

# 480 patients undergoing testing for COVID-19.

NOP	Saliva			
	Negative	Positive		
Negative	131	18		
Positive	15	37		

#### Table 2 - Demographic and clinical characteristics of 201 patients with suspected

	NOP-/saliva-	NOP-/saliva+	NOP+/saliva-	NOP+/saliva+	<i>P</i> -value	P-value
	(G1)	(G2)	(G3)	(G4)	G3 vs G4	G2 vs G4
	N = 131	N = 18	N = 15	N = 37		
	n(%) or	n(%) or	n(%) or	n(%) or		
	median (IQR)	median (IQR)	median (IQR)	median (IQR)		
Age	40 (31 - 52)	30 (29 - 49)	32 (26 - 44)	39 (30 - 48)	0.312	0.907
Gender						
Male	49 (62)	2 (11)	5 (33)	18 (48.6)		
Female	81 (38)	16 (89)	10 (67)	19 (51.4)	0.484	0.016
Delay						
between	6 (4 - 9)	6 (5 - 9)	7 (5 - 8)	4 (4 - 6)	0.039	0.029
symptoms						
and						
collection						
(days)						
Symptoms						
Fever	43 (33)	6 (33)	7 (47)	19 (51)	1.0	0.332
Anosmia	37 (28)	8 (44)	11 (79)	18 (53)	0.188	0.996
Ageusia	38 (29)	7 (39)	11 (73)	13 (35)	0.028	1.0
Nasal	73 (56)	11 (61)	10 (67)	29 (78)	0.60	0.30
congestion	76 (58)	7 (39)	5 (33)	19 (51)	0.38	0.56
Coryza	88 (68)	12 (66)	9 (60)	26 (70)	0.697	0.1.0
Myalgia	62 (48)	9 (50)	7 (47)	19 (51)	1.0	1.0
Arthralgia	97 (75)	12 (66)	11 (73)	30 (81)	0.80	0.314
Cough						

COVID-19 tested with RT-PCR in both saliva and NOP samples.

Notes: NOP- naso/oropharyngeal swab; G1 – group 1; G2 – group 2; G3 – group 3; G4 – group 4; IQR –

interquartile range.

#### Figure 1 518



#### Figure 2 534



#### Figure 3 545

![](_page_23_Figure_3.jpeg)

#### 555 Figure Legends

556

**Figure 1** - Comparison of RT-PCR cycle thresholds between naso-oropharyngeal and saliva samples in 37 patients with positive results in both samples. The coefficients of the regression lines are 0.79 (P < 0.001) for gene E and 0.74 (P = 0.002) for gene S.

560

#### 561 Figure 2

562 **A** - Violin plots showing the distribution of cycle thresholds in nasal-oropharyngeal 563 swabs (NOP) and saliva samples for the two genes (E and S) amplified by RT-PCR. 564 Boxplots shows median, interquartile range and range as standard. Analysis of the 37 565 patients with positive results in both sample types by comparing the distributions of cycle 566 thresholds between NOP and saliva samples. Paired Wilcoxon's rank-sum test was used, 567 in which *P*-values were < 0.001 for genes E and S.

B - Distribution of SARS-CoV-2 RT-PCR cycle thresholds in the 52 positive nasaloropharyngeal swabs (NOP) samples stratified by RT-PCR results in saliva
(NOP+/saliva- *versus* NOP+/saliva+). Boxplots shows median, interquartile range and
range as standard. Distributions were compared by using paired Wilcoxon's rank-sum
test, in which *P*-values were 0.21 and 0.35 for genes E and S, respectively.

573

**Figure 3** - Relationship between illness course (i.e. time elapsed between symptom onset and sample collection) and cycle threshold values for nasal-oropharyngeal swabs (NOP) (left-hand panels) and saliva samples (right-hand panels). In the NOP samples, the regression coefficients for cycle threshold (delay of log<sub>2</sub>-days) for genes E and S were 0.5 (P = 0.72) and 1.1 (P = 0.42), respectively; the regression coefficients for saliva samples were 0.04 (P = 0.98) and -0.26 (P = 0.87) for genes E and S, respectively.